RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially approved for clinical trials

CAR-T Digest - August 2020

Weekly Digest - April 2026

01 April 2026: RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially approved for clinical trials

RemeGen’s dual-target ADC, RC288, has received clinical trial approval from China’s NMPA to initiate a Phase 1/2a study in patients with advanced or metastatic solid tumors
This approval is important as patients with advanced solid tumors often face limited treatment options and poor outcomes, highlighting the need for new therapies
The study will be conducted as a multicenter, open-label Phase 1/2a trial, evaluating safety, tolerability, pharmacokinetics, and early anti-tumor activity
RC288 is a bispecific antibody-drug conjugate targeting PSMA and B7-H3, two proteins involved in tumor growth and immune escape and widely expressed across multiple solid tumors
With encouraging preclinical anti-tumor activity and safety signals, RC288 represents a next-generation ADC approach with the potential to offer a new treatment option in this setting